Our Financial
Performance

In 2021, our team worked together to deliver strong results across our core business with impressive EYLEA and Dupixent growth, while also helping address the ongoing pandemic by delivering REGEN-COV to millions of patients. For 2022, we remain focused on building on EYLEA's success, expanding approvals and patient reach for Dupixent, pursuing new indications for Libtayo, and reading out data from our oncology pipeline – all while continuing to progress our diversified earlier-stage pipeline. We also remain committed to our efforts to fight the COVID-19 pandemic and address the significant need for effective treatments and preventative approaches to SARS-CoV-2. With growth continuing across our existing portfolio and investments in our Research & Development engine supported by our strong balance sheet, we are well positioned for sustainable long-term growth.
Video of Regeneron employee being interviewed about 2021 operational growth and plans for 2022.

Key 2021 business updates

$16.1B
in total revenue
in 2021
$9.9B
in 2021 revenue
excluding REGEN-COV1
$2.9B
reinvested in our Research
& Development efforts
$1.7B
repurchased through share
buyback programs
Eylea generated $9.4 million dollars in 2021, a 19% increase over 2020. Eylea generated $9.4 million dollars in 2021, a 19% increase over 2020.
$9.4
billion
in global net product sales
(19% increase over 2020)2
Dupixent generated $6.2 billion in 2021, a 53% increase over 2020. Dupixent generated $6.2 billion in 2021, a 53% increase over 2020.
$6.2
billion
in global net product sales
(53% increase over 2020)3
Libtayo generated $458 million in 2021, a 32% increase over 2020. Libtayo generated $458 million in 2021, a 32% increase over 2020.
$458
million
in global net product sales
(32% increase over 2020)4

Read our Shareholder Letter and more in our 2022 Proxy statement

notable awards

Civic 50: Most Community-Minded Companies in the Nation

Dow Jones Sustainability Index: World and North America

Fast Company: World Changing Ideas (Pandemic Response)

Forbes: World’s Top Female Friendly Companies

Best Workplaces for Women trophy.

Great Place to Work Ireland: Best Workplaces for women

Great Place to Work: Fortune 100 Best Companies to Work For

IDEA Pharma: Pharmaceutical Invention Index, 2021

Newsweek: America’s Most Responsible Companies

CONTINUED
REVENUE GROWTH1

$4.26B $4.26B total revenue 2017 $5.15B $5.15B total revenue 2018 $6.56B $6.56B total revenue 2019 $8.311B $186M $8.497B total revenue $186M REGEN-COV revenue 2020 $9.882B $6.190B $16.072B total revenue $6.190B REGEN-COV revenue 2021
REGEN-COV revenue

1 Revenues excluding REGEN-COV is a measure not calculated in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Please see Table 3 of Regeneron’s earnings release announcing its financial and operating results for the quarter and year ended December 31, 2021 for a reconciliation of this measure to the most directly comparable GAAP financial measure.

2 Regeneron records net product sales of EYLEA in the U.S and Bayer records net product sales of EYLEA outside the U.S.

3 Sanofi records global net product sales of Dupixent.

4 Regeneron records net product sales of Libtayo in the U.S. and Sanofi records net product sales of Libtayo outside the U.S.

Back to top